No abstract available
MeSH terms
-
Allografts
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Benzamides / administration & dosage
-
Benzamides / therapeutic use*
-
Dasatinib
-
Disease Progression
-
Drug Design
-
Fusion Proteins, bcr-abl / antagonists & inhibitors
-
Fusion Proteins, bcr-abl / genetics
-
Hematopoietic Stem Cell Transplantation
-
Humans
-
Imatinib Mesylate
-
Imidazoles / administration & dosage
-
Imidazoles / therapeutic use
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
-
Molecular Targeted Therapy*
-
Neoplasm Staging
-
Piperazines / administration & dosage
-
Piperazines / therapeutic use*
-
Point Mutation
-
Protein Kinase Inhibitors / therapeutic use*
-
Pyridazines / administration & dosage
-
Pyridazines / therapeutic use
-
Pyrimidines / administration & dosage
-
Pyrimidines / therapeutic use*
-
Randomized Controlled Trials as Topic
-
Thiazoles / administration & dosage
-
Thiazoles / therapeutic use
Substances
-
Benzamides
-
Imidazoles
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyridazines
-
Pyrimidines
-
Thiazoles
-
ponatinib
-
Imatinib Mesylate
-
Fusion Proteins, bcr-abl
-
nilotinib
-
Dasatinib